Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
AstraZeneca
McKinsey
Colorcon
Johnson and Johnson

Last Updated: March 23, 2023

Investigational Drug Information for HSK3486


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


What is the development status for investigational drug HSK3486?

HSK3486 is an investigational drug.

There have been 28 clinical trials for HSK3486. The most recent clinical trial was a Phase 3 trial, which was initiated on December 8th 2020.

The most common disease conditions in clinical trials are Depressive Disorder, Liver Diseases, and Renal Insufficiency, Chronic. The leading clinical trial sponsors are Sichuan Haisco Pharmaceutical Group Co., Ltd., Sichuan Haisco Pharmaceutical Group Co., Ltd, and Haisco-USA Pharmaceuticals, Inc.

There are two US patents protecting this investigational drug and thirty-seven international patents.

Recent Clinical Trials for HSK3486
TitleSponsorPhase
Safety and Efficacy of HSK3486 Compares to Propofol for Induction of General Anesthesia in Adults With Elective SurgeryHaisco-USA Pharmaceuticals, Inc.Phase 3
Dose-Finding and Human Abuse Potential Study Of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant UsersHaisco-USA Pharmaceuticals, Inc.Phase 1
Efficacy and Safety of HSK3486 Compared to Propofol for Adults Undergoing Elective Surgery With General AnesthesiaHaisco-USA Pharmaceuticals, Inc.Phase 3

See all HSK3486 clinical trials

Clinical Trial Summary for HSK3486

Top disease conditions for HSK3486
Top clinical trial sponsors for HSK3486

See all HSK3486 clinical trials

US Patents for HSK3486

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
HSK3486 See Plans and Pricing Use of GABAA receptor reinforcing agent in preparation of sedative and anesthetic medicament HAISCO CHENGDU PHARMACEUTICAL TECHNOLOGY CO., LTD. (Chengdu, Sichuan, CN) See Plans and Pricing
HSK3486 See Plans and Pricing Phenol derivative and preparation method and use in medicine thereof Sichuan Haisco Pharmaceutical Co., Ltd. (Chengdu, CN) See Plans and Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for HSK3486

Drugname Country Document Number Estimated Expiration Related US Patent
HSK3486 Australia AU2015311394 2034-09-04 See Plans and Pricing
HSK3486 Brazil BR112017004448 2034-09-04 See Plans and Pricing
HSK3486 Canada CA2959812 2034-09-04 See Plans and Pricing
HSK3486 China CN105579034 2034-09-04 See Plans and Pricing
HSK3486 Eurasian Patent Organization EA035649 2034-09-04 See Plans and Pricing
HSK3486 Eurasian Patent Organization EA201790525 2034-09-04 See Plans and Pricing
HSK3486 European Patent Office EP3189834 2034-09-04 See Plans and Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
AstraZeneca
McKinsey
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.